<DOC>
	<DOCNO>NCT01069770</DOCNO>
	<brief_summary>The purpose study see whether neoadjuvant administration Sunitinib reduce size primary kidney tumor patient metastatic disease undergo cytoreductive surgery . The study also assess safety neoadjuvant Sunitinib , objective response rate , respectability primary tumor , quality life , survival advantage .</brief_summary>
	<brief_title>Neoadjuvant Sunitinib Treatment Metastatic Clear Cell Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description>Primary objective : 1 . Response rate primary tumor base RECIST criterion Secondary objective : 1 . Resectability base R0 resection rate ( negative margin ) 2 . Toxicities therapy neoadjuvant Sunitinib renal cell carcinoma 3 . Quality life assess EORTC QLQ-C30 questionnaire Korean version 4 . To assess efficacy neoadjuvant therapy Sunitinib evaluating time progression 5 . Overall survival rate Sunitinib therapy 6 . Pathologic evaluation Sunitinib therapy : change necrosis microvessel density</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Biopsy proven RCC component clear cell type histology Clinical stage TxNxM+ At least one site measurable disease define RECIST criterion Potential candidate cytoreductive nephrectomy Favorable intermittent risk group accord MSKCC risk factor model ECOG performance status 0 1 Adequate organ function define : AST ALT less equal 2.5 time upper limit normal Bilirubin le equal 1.5 time upper limit normal Absolute neutrophil count ( ANC ) great equal 1500/mL Platelets great equal 100,000/mL Hemoglobin great equal 9.0 g/dL Serum calcium less equal 12.0 mg/dL Serum creatinine less equal 1.5 time upper limit normal Male female , 18 year age old Women childbearing potential must NOT pregnant ( confirmed negative pregnancy test ) Signed informed consent form indicate patient acceptable representative inform part trial prior Sunitinib administration ( enrollment ) Willingness ability comply study procedures History another primary malignancy within 5 year , exception nonmelanoma skin cancer situ carcinoma uterine cervix . NCI CTCAE grade 3 hemorrhage within 4 week commence Sunitinib therapy . Presence brain metastasis screen period Ongoing cardiac dysrhythmias NCI CTCAE grade 2 , atrial fibrillation grade prolongation QTc interval 450 millisecond ( msec ) male 470 msec female Hypertension control medication Concurrent treatment therapeutic dos coumadin low dose coumadin 2 mg orally daily deep vein thrombosis prophylaxis allow . Current treatment another therapeutic clinical trial . Supportive care trial nontreatment trial allow . Inability swallow oral medication , presence active inflammatory bowel disease , partial complete bowel obstruction chronic diarrhea . Concurrent medication know potent CYP3A4 inhibitor inducer and/or dose 7 12 day date randomization . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study . Any follow within 12 month prior study drug administration : severe/unstable angina , myocardiac infarction , coronary artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , include transient ischemic attack , pulmonary embolism . Known hypersensitivity Sunitinib Women breastfeed â€» Note At screening , resectability primary tumor influence patient enrollment . Physicians describe resectability ( `` resectable '' `` unresectable '' ) screen discretion , decide primary tumor `` unresectable '' , specify reason unresectable status follow : invasion neighbor organ , proximity vital structure vessel , bulky regional lymph node , vascular invasion , burden metastatic disease , others .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Neoadjuvant Therapy</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Clear Cell Renal Cell Carcinoma</keyword>
	<keyword>Metastasis</keyword>
</DOC>